Nicardipine: A hypotensive dihydropyridine-type calcium antagonist with a peculiar cerebrovascular profile

Clinical and Experimental Hypertension

Volumn 30, Issue 8, 2008, Pages 808-826

  Amenta, Francesco ^a,c   Tomassoni, Daniele ^a   Traini, Enea ^a   Mignini, Fiorenzo ^a   Veglio, Franco ^b  

^a UNIVERSITY OF CAMERINO   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Dipartimento di Medicina Sperimentale e Sanità Pubblica   (Italy)

Author keywords

Hypertension; Nicardipine; Stroke; Subarachnoid haemorrhage; Vascular dementia

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIZOCILPINE; FLUNARIZINE; GLYCERYL TRINITRATE; HYDRALAZINE; INDENOLOL; LERCANIDIPINE; LIDOFLAZINE; MANIDIPINE; METHACHOLINE; NICARDIPINE; NIMODIPINE; NITROPRUSSIDE SODIUM; VASODILATOR AGENT; VERAPAMIL;

ANTIHYPERTENSIVE ACTIVITY; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; DRUG IMPLANT; DRUG RELEASE; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; HUMAN; MULTIINFARCT DEMENTIA; NEUROPROTECTION; NONHUMAN; RENOVASCULAR HYPERTENSION; STROKE; SUBARACHNOID HEMORRHAGE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CEREBROVASCULAR DISORDERS; DEMENTIA, VASCULAR; HUMANS; NICARDIPINE; STROKE; SUBARACHNOID HEMORRHAGE;

EID: 56549108336     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960802580190     Document Type: Conference Paper

References (134)

1. Takenaka T, Usuda S, Nomura T, Maeno H, Sado T. Vasodilator profile of a new 1,4-dihydropyridine derivative, 2,6-dimethyl-4(3-nitrophenyl)-1,4 dihydropyridine-3,5dicarboxilic acid 3-(2-N-benzyl-N-methylamino)-ethyl ester 5-methyl ester hydrochloride (YC-93). Arznm Forsch. 1976;26:2172-2178.
2. Iwanami M, Shibanuma T, Fujimoto M, Kawai R, Tamazawa K, Takenaka T, Takahashi K, Murakami M. Synthesis of new water-soluble dihydropyridine vasodilators. Chem Pharm Bull (Tokyo). 1979;27:1426-1440.
3. Takenaka T, Handa J. Cerebrovascular effects of YC-93, a new vasodilator, in dogs, monkeys and human patients. Int J Clin Pharmacol Biopharm. 1979;17:1-23.
4. Takenaka T, Asano M, Shiono K, Shibasaki M, Inagaki O. Cardiovascular pharmacology of nicardipine in animals. Br J Clin Pharmacol. 1985;20 (Suppl. 1):7S-22S.
5. Otomo E. Clinical effects of YC-93 (nicardipine hydrochloride) in patients with various cerebrovascular diseases. Clin Rep. 1979;13:1207-1213.
6. Yamada T, Muroga T, Kimura J. Tourniquet-induced ischemia and somatosensory evoked potentials. Neurology. 1981;31:1524-1529.
7. Sakamoto N, Terai M, Takenaka T, Maeno H. Inhibition of cyclic AMP phosphodiesterase by 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5- dicarboxylic acid 3-[2-(N-benzyl-N-methylamino)] ethyl ester 5-methyl ester hydrochloride (YC-93), a potent vasodilator. Biochem Pharmacol. 1978;27:1269-1274.
8. Satoh K, Yanagisawa T, Taira N. Mechanisms underlying the cardiovascular action of a new dihydopyridine vasodilator, YC-93 (nicardipine). Clin Exp Pharmacol Physiol. 1980;7:249-262.
9. Terai M, Takenaka T, Maeno H. Inhibition of calcium influx in rabbit aorta by nicardipine hydrochloride (YC-93). Biochem Pharmacol. 1981;30:375-378.
10. Casteels R, Droogmans G. Exchange characteristics of the noradrenaline-sensitive calcium store in vascular smooth muscle cells or rabbit ear artery. J Physiol. 1981;317:263-279.
11. Yamamoto M, Ohta T, Noburo T. Mechanism of relaxant actions of nicardipine, a new calcium antagonist, on isolated dog cerebral and mesenteric arteries. Stroke. 1983;14:270-275.
12. Fujiwara S, Kuryama H. Effects of agents that modulate potassium permeability on smooth muscle cells of the guinea-pig basilar artery. Br J Pharmacol. 1983;79:23-35.
13. Struyker-Boudier HAJ, Smits JFM, De Mey JGR. The pharmacology of calcium antagonists: A review. J Cardiovasc Pharmacol. 1990;15 (Suppl. 4):S1-S10.
14. Hofman F, Nastainezyk W, Rohrkasten A, et al. Regulation of the L-type calcium channel. Trends Pharmacol Sci. 1987;8:393-398.
15. Freedman DD, Waters DD. Second generation dihydropyridine calcium antagonists: Greater vascular selectivity and some unique applications. Drugs. 1997;34:578-598.
16. Amenta F, Ferrante F, Sabbatini M, Ricci A. Quantitative image analysis study of the cerebral vasodilatory activity of nicardipine in spontaneously hypertensive rats. Clin Exper Hypertens A. 1994;16:359-371.
17. Karashima T, Kuriyama H. Electrical properties of smooth muscle cell membrane and neuromuscular transmission in the guinea-pig basilar artery. Br J Pharmacol. 1981;74:495-504.
18. Suzuki H, Fujiwara S. Neurogenic electrical response of single smooth muscle cells of the dog middle cerebral artery. Circ Res. 1982;51:751-759.
19. Uski TK, Andersson KE. Effect of prostanoids on isolated feline cerebral arteries, II: Roles of extra- and intracellular calcium for the prostaglandin F2α-induced contraction. Acta Physiol Scand. 1984;120:197-205.
20. Wendling WW, Harakal C. Comparative action of pentobarbital and verapamil on canine cerebral and pheripheral arteries in vitro. Res Commun Chem Pathol Pharmacol 1985;49:189-202.
21. Sasaki T, Kassel NF, Zuccarello M. Dependence of cerebral arterial contractions on intracellulary stored calcium. Stroke. 1986;17:95-97.
22. Salomon JB, Torregrosa G, Miranda FJ, Alabadì JA, Alvarez C, Alborch E. Calcium entry blockers inhibit prostaglandin F2α-induced cerebrovascular contractile response in goats. Eur J Pharmacol 1991;203:33-39.
23. 2+ in isolated human cerebral arteries. Eur J Pharmacol. 1992;229:83-89.
24. Brading AF. Maintenance of ionic composition. Br Med Bull. 1979;35:227-234.
25. Blaustein MP. Sodium ions, calcium ions, blood pressure regulation and hypertension: A reassessment and a hypothesis. Am J Physiol. 1981;294:752-761.
26. Okada T, Shibuya M, Suzuki Y, Ikegaki I, Kageyama N, Asano T, Hidaka H. Effect of the intracellular calcium antagonist HA1004 on cerebral blood flow in rats. Neurol Med Chir (Jap). 1988;28:625-630.
27. Grotta J, Spydell J, Pettigrew C, Ostrow P, Hunter D. The effect of nicardipine on neuronal function following ischemia. Stroke. 1986;17:213-219.
28. Hadani M, Young W, Flamm ES. Nicardipine reduces calcium accumulation and electrolyte derangement in regional ischemia in rats. Stroke. 1988;19:1125-1132.
29. Whiting RL. Animal pharmacology of nicardipine and its clinical relevance. Am J Cardiol. 1987;59:3J-9J.
30. Alps BJ, Calder C, Hass WK, Wilson AD. Comparative protective effect of nicardipine, flunarizine, lidoflazine and nimodipine against ischaemic injury in the hippocampus of the mongolian gerbil. Br J Pharmacol. 1988;93:877-883.
31. Sakabe T, Nagai I, Ishikawa T, Takeshita H, Masuda T, Matsumoto M, Tateishi A. Nicardipine increases cerebral blood flow but does not improve neurologic recovery in a canine model of complete cerebral ischemia. J Cer Blood Flow Metab. 1986;6:684-690.
32. Dote K. Cerebral hemodynamics of post-ischemic delayed hypoperfusion (PDH) and the effects of nicardipine on the PDH. Jpn J Anesthesiol. 1990;39:357-366.
33. Iwatsuki N, Ono K, Takahashi M, Tajima T. The effect of nicardipine given after 10 minutes complete global cerebral ischemia on neurologic recovery. J Anesth (Jap). 1990;4:337-342.
34. Kucharczyk J, Chew W, Derugin N, Moseley M, Rollin C, Berry I, Norman D. Nicardipine reduces ischemic brain injury. Stroke. 1989;20:268-274.
35. Montero JL, Grau M, Balasch J. Nicardipine: Protection against brain hypoxia. Drugs Exp Clin Res. 1986;12:377-380.
36. Grotta J, Pettigrew C, Rosenbaum D, Reid C, Rhoades H, McCandless D. Efficacy and mechanism of action of a calcium channel blocker after global cerebral ischemia in rats. Stroke. 1988;17:447-454.
37. Grotta JC, Picone CM, Dedman JR, Rhoades HM, Strong RA, Earls RM, Yao, LP. Neuronal protection correlates with prevention of calcium-calmodulin binding in rats. Stroke. 1990;21 (Suppl. 3):III-28-III-31.
38. Abe K. Effect of nicardipine hydrochloride on ischemic brain edema. Neurol Med Chir (Jap). 1987;27:819-824.
39. Ricci A, Sabbatini M, Tomassoni D, Mignini F, Petrelli C, Amenta F. Neuronal populations of rat cerebral cortex and hippocampus expressed a higher density of L-type calcium channel than corresponding cerebral vessels. Clin Exp Hypertens. 2002;24:715-726.
40. Schmidt-Kastner R, Freund TF. Selective vulnerability of the hippocampus in brain ischemia. Neuroscience. 1991;40:599-636.
41. Alps BJ, Calder C, Wilson AD. The effect of nicardipine on "delayed neuronal death" in the ischaemic gerbil hippocampus. Br J Pharmacol Proc. Suppl. 1986;88:250.
42. Hewitt K, Corbett D. Combined treatment with MK-801 and nicardipine reduced global ischemic damage in the gerbil. Stroke. 1992;23:82-86.
43. Asano T, Ikegaki I, Satoh S, Mochizuki D, Hidaka H, Suzuki Y, Shibuya M, Sugita K. Blockade of intracellular actions of calcium may protect against ischemic damage to the gerbil brain. Br J Pharmacol. 1991;103:1935-1938.
44. Nagaoka A. Pharmacological prevention of cerebral stroke in stroke-prone spontaneously hypertensive rats. J Hypertens. 1986;4 (Suppl.):S523-S525.
45. Suzuki S. Influence of duration of antihypertensive treatment on experimental cerebral ischemia in SHRSR. Nippon Ika Daigaku Zasshi. 1987;54:118-127.
46. Suzuki S, Katayama Y, Memezawa H, Sugimoto S, Nagazumi A, Terashi A. Influence of long-term antihypertensive treatment on cerebral ischemia induced by bilateral carotid ligation in stroke-prone spontaneously hypertensive rats. Protective effect of nicardipine hydrochloride. Med Consult New Remed (Jap). 1987;24:1043-1046.
47. Amenta F, Strocchi P, Sabbatini M. Vascular and neuronal hypertensive brain damage: Protective effect of treatment with nicardipine. J Hypertens. 1996;14 (Suppl.):S29-S35.
48. Sabbatini M, Bellagamba G, Casado A, Tayebati SK, Venarucci D, Amenta F. Protective effect of treatment with nicardipine on cerebrovascular tree of spontaneously hypertensive rats. Clin Exp Hypertens. 2001a;23:143-155.
49. Sabbatini M, Bellagamba G, Vega JA, Amenta F. Effect of antihypertensive treatment on peripheral nerve vasculature in spontaneously hypertensive rats. Clin Exp Hypertens. 2001;23:157-66.
50. Sabbatini M, Mignini F, Venarucci D, Vega JA, Amenta F. Effect of nicardipine treatment on the expression of neurofilament 200 KDa immunoreactivity in the brain of spontaneously hypertensive rats. Clin Exp Hypertens. 2001;23:127-141.
51. Sabbatini M, Tomassoni D, Di Tullio MA, Amenta F. Neuroprotective effect of treatment with calcium antagonists on hypertensive retina. Clin Exp Hypertens. 2002;24:727-740..
52. Tomassoni D, Mancinelli G, Mignini F, Sabbatini M, Amenta F. Quantitative image analysis of choroid and retinal vasculature in SHR: A model of cerebrovascular hypertensive changes? Clin Exp Hypertens. 2002;24:741-752.
53. Kaplan JA. Clinical considerations for the use of intravenous nicardipine in the treatment of postoperative hypertension. Am Heart J. 1990;119:443-446.
54. Pepine CJ. Intravenous nicardipine: Cardiovascular effects and clinical relevance. Clin Ther. 1988;10:316-325.
55. Cluzel P, Chatellier G, Rivalan J, et al. Predictive factors of the blood pressure fall induced by intravenous nicardipine. J Cardiovasc Pharm. 1989;13:370-375.
56. Escande M, David D, Diadema B. Effets antihypertenseurs de la nicardipine intraveineuse dans 1'hypertension arterielle du sujet age. Therapie. 1989;44:161-165.
57. Lambert CR, Pepine CJ. Effects of intravenous and intracoronary nicardipine. Am J Cardiol. 1989;64:8H-15H.
58. Ryman KS, Kubo SH, Shaknovich A, et al. Influence of baseline hemodynamic status and sympathetic activity on the response to nicardipine, a new dihydropyridine, in patients with hypertension or chronic congestive heart failure. Clin Pharmacol Ther. 1987;41:483-489.
59. Silke B, Hafizullah M, Frais MA, et al. Haemodynamic effects of nicardipine in acute myocardial infarction. Postgrad Med J. 1984;60:29-34.
60. Sorkin EM, Clissold SP. Nicardipine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs. 1987;33:296-345.
61. Fischell TA, Maheshwari A. Current applications for nicardipine in invasive and interventional cardiology. J Invasive Cardiol. 2004;16:428-432.
62. Curran MP, Robinson DM, Keating GM. Intravenous nicardipine: Its use in the short-term treatment of hypertension and various other indications. Drugs. 2006;66:1755-1782.
63. Sahney S. A review of calcium channel antagonists in the treatment of pediatric hypertension. Paediatr Drugs. 2006;8:357-373.
64. Lambert CR, Pepine CJ. Acute antianginal hemodynamic effects of nicardipine in coronary artery disease. American Heart Journal. 1990;119:457-462.
65. Lambert CR, Pepine CJ. Critical drug appraisal: Nicardipine. Drug Therapy. 1990;20:55-61.
66. Broadhurst PA, Brigden G, Heber M, et al. Twenty-four hour ambulatory blood pressure profile of a new, sustained-release preparation of nicardipine. Cardiovascular Drugs and Therapy. 1990;4:435-438.
67. Palatini P, Businaro R, Racioppa A, et al. The effect of slow-release nicardipine on 24-hour blood pressure and blood pressure response to exercise. Curr Ther Res. 1990;47:759-764.
68. Sega R, Centonze F, Borgnino C, et al. Repeated 24-hour ambulatory blood pressure rnonitoring of essential hypertensives during long-term treatment with slow-release nicardipine. Curr Ther Res. 1988;43:1053-1062.
69. Maetzel FK, Teufel WE, Griebel A, Glocke MH. Double-blind, randomized comparative study of the antihypertensive effect of nicardipine slow-release and nifedipine slow-release in hypertensive patients with coronary heart disease. Cardiovasc Drug Ther. 1991;5:647-654.
70. Cavatorta A, Pucci F, Ghirarduzzi A, et al. Sustained-release nicardipine corrects hypertension and cardiac hypertrophy in renal insufficiency. Curr Ther Res. 1990;48:298-307.
71. Dessi-Fulgheri P, Di Noto G, Catalina R, et al. Effects of slow-release nicardipine on blood pressure, diuresis, and atrial natriuretic factor in hypertensives. Curr Ther Res. 1990;48:395-402.
72. Herpin D. Cerveau et hypertension artèrielle. Première partie. Aspects physiologique et physiopathologique. Ann Cardiol Angiol. 1989;38:269-272.
73. Mazzola C, Borgnino C, Colombo D, et al. Antihypertensive and hemodynamic effects of slow-release nicardipine. Int J Clin Pharmacol Ther Toxic. 1988;26:503-508.
74. Stornello M, Valvo EV, Scapellato L. Effect of sustained-release nicardipine, chlorthalidone, and the two drugs combined in patients with mild to moderate hypertension. Curr Ther Res. 1990;47:405-411.
75. Forette F, McClaran J, Hervy MP, et al. Nicardipine in elderly patients with hypertension: A review of experience in France. Am Heart J. 1989;117:256-261.
76. Krakoff LR. Nicardipine monotherapy in ambulatory elderly patients with hypertension. Am Heart J. 1989;117:250-255.
77. Leonetti G. The clinical performance of nicardipine in elderly hypertensive patients with concomitant disease. Am Heart J. 1989;117:266-269.
78. Littler WA. Nicardipine in the elderly hypertensive: A review of experience in the United Kingdom. Am Heart J. 1989;117:262-265.
79. Amenta F, Mignini F, Rabbia F, Tomassoni D, Veglio F. Protective effect of anti-hypertensive treatment on cognitive function in essential hypertension: Analysis of published clinical data. J Neurol Sci. 2002;204:147-151.
80. Sabbatini M, Strocchi P, Amenta F. Nicardipine and treatment of cerebrovascular diseases with particular reference to hypertension-disorders. Clin Exp Hypertens. 1995;17:719-750.
81. Gaab MR, Czech T, Korn A. Intracranial effects of nicardipine. Br J Clin Pharmacol. 1985;20:67S-74S.
82. Martì Masso JF, Lozano R. Nicardipine in the prevention of cerebral infarction. Clin Ther. 1990;12:344-351.
83. Lozano R, Balaguer A. Nicardipine in the treatment of outpatients with cerebrovascular disorders. Clin Ther. 1991;13:496-499.
84. Ribas Mundò M, Lozano R. The influence of nicardipine in patients with high risk of stroke. J Cardiovasc Pharmacol. 1990;16 (Suppl. 2):S16-S19.
85. Otomo E, Tsuru M, Kutsuzawa T, Kogure H, Terashi A, Tazaki Y, Araki G, Ito E, Sekimoto H, Omae T, Sawada T, Kito S, Fuzishima M, Goto F. The clinical efficacy of Bay-e-9736 for the treatment of cerebrovascular disorders. Geriatr Med (Jap). 1986;24:1-81.
86. Nishikawa T, Omote K, Namiki A, Takahashi T. The effect of nicardipine on cerebrospinal fluid pressure in humans. Anesth Analg, 1986;65:507-510.
87. Kawaguchi M, Hitoshi F, Kurehara K, Yamada M. Effects of nicardipine on cerebral vascular responses to hypocapnia and blood flow velocity in the middle cerebral artery. Stroke. 1991;22:1170-1172.
88. Yoshinaga S, Kimura M, Tanaka T, Ueno, Y, Tanaka, A. Effects of oral administration of nicardipine on cerebral blood flow in hypertensive patients. Diagnosis Treatment (Jap). 1991;79 (Suppl.):2686-2690.
89. Flamm ES, Adams HP, Beck DW, Pinto RS, Marler JR, Walker MD, Godersky JC, Loftus CM, Biller J, Boarini DJ, O'Dell C, Banwart K, Kongable G. Dose-escalation study of intravenous nicardipine in patients with aneurysmal subarachnoid hemorrhage. J Nerosurg. 1988;68:393-400.
90. Montarry M, Chacornac R, Philippon B, Bouchet CI, Guichard P. Effects of an intravenous injection of nicardipine on cerebral blood flow in subarachnoid hemorrhage caused by intracranial aneurysm. Agressologie. 1989;30:411-415.
91. Combes P, Fauvage B. Systemic vasomotor interaction between nicardipine and hypocapnic alkalosis in man. Intensive Care Med. 1992;18:89-92.
92. Beck DW, Adams HP, Flamm ES, Godersky JC, Loftus CM. Combination of aminocaproic acid and nicardipine in treatment of aneurysmal subarachnoid hemorrhage. Stroke. 1988;19:63-67.
93. Fujita K, Yamashita H, Masamura M, Ehara K, Tamaki N, Matsumoto S. The effects of ticlopidine and nicardipine on the prevention of symptomatic vasospasm after aneurysmal rupture. No Shinkei Geka (Jap). 1988;16:741-746.
94. Feigin VL, Rinkel GJ, Algra A, Vermeulen M, van Gijn J. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2000;2:CD000277.
95. Kasuya H, Onda H, Sasahara A, Takeshita M, Hori T. Application of nicardipine prolonged-release implants: Analysis of 97 consecutive patients with acute subarachnoid hemorrhage. Neurosurgery. 2005;56:895-902.
96. Barth M, Capelle HH, Weidauer S, Weiss C, Munch E, Thome C, Luecke T, Schmiedek P, Kasuya H, Vajkoczy P. Effect of nicardipine prolonged-release implants on cerebral vasospasm and clinical outcome after severe aneurysmal subarachnoid hemorrhage: A prospective, randomized, double-blind phase IIa study. Stroke. 2007;38:330-336.
97. Medical Reseach Council Working Party. Stroke and coronary heart disease in mild hypertension: Risk factors and the value of treatment. Br Med J 1988;296:1565-1570.
98. Barry DI, Vorstrup S, Jarden JO, Svendsen UG, Braendstrup O, Graham DI, Strandgaard S. Effects of antihypertensive drugs on the cerebral circulation. Acta Med Scand. 1993;677 (Suppl.):143-147.
99. Inzitari D, Poggesi A. Calcium channel blockers and stroke. Aging Clin Exp Res. 2005;17:16-30.
100. Angeli F, Verdecchia P, Reboldi GP, Gattobigio R, Bentivoglio M, Staessen JA, Porcellati C. Calcium channel blockade to prevent stroke in hypertension: A meta-analysis of 13 studies with 103,793 subjects. Am J Hypertens. 2004;17:817-822.
101. Yao, L.P, Ding, D.Y. Effect of nicardipine on somatosensory evoked potentials in patients with acute cerebral infarction. J Neurol Neurosurg Psychiat 1990; 53: 844-846.
102. Rosenbaum DM, Zabramski J, Frey J, Yatsu F, Marler L, Spetzler R, Grotta J. Early treatment of ischemic stroke with a calcium antagonist. Stroke. 1991;22:437-441.
103. Lisk DR, Grotta GC, Lamki LM, Tran HD, Taylor JW, Molony DA, Barron BJ. Should hypertension be treated after acute stroke? Arch Neurol. 1993;50:855-862.
104. Uematsu D, Watanabe S, Katayama T. Nicardipine improves cerebral hemodynamics in acute and subacute stroke. Neurology. 1992;42 (4 Suppl. 3):395.
105. Gamèz NM, Soto Mas JA, Aguilar Martinez JL, Bermùdez Garcia JM, Salim A, Ramos Jimènez A, Gil Extremera B. Ensayo clìnico controlado a doble ciego: Nicardipina frente a placebo en la isquemia cerebral focal aguda. Med Clin (Barc). 1988;90:690-692.
106. Rosenbaum DM, Grotta JC, Yatsu FK, Picone CM, Pettigrew LC, Bratina P, Zabramski J, Spetzler R, Lopez L, Marler J, Ellis D. A pilot study of nicardipine for acute ischemic stroke. The nicardipine study group. In: Hartmann A, Kuschinsky W, eds. Cerebral ischemia and calcium. Berlin: Springer; 1989, pp. 367-372.
107. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187.
108. Handa J, Matsuda M, Nakasu Y, Nakasu S, Kidooka M, Watanbe K. Clinical effect of a new 1,4-dihydropyridine derivative, YC-93, in patients with cerebrovascular diseases. Arch Jpn Chir. 1979;48:400-403.
109. Miyamoto T. Effect of long-term treatment with YC-93 (Nicardipine HCl), a 1,4,-dihydropyridine derivative, on obstructive cerebrovascular disorders. Clin Rep (Jap). 1981;15:426-434.
110. Saku J. Clinical use of YC-93 (Nicardipine HCl) in patients with cerebrovascular disorders, part 2: Long-term use of YC-93. Clin Rep (Jap). 1981;15:233-242.
111. Tajika Y. Clinical study of nicardipine hydrochloride (Perdipine) in patients with cerebral vascular disorders. Basic Clin Med (Jap). 1982;16:315-318.
112. Tamura M. Clinical efficacy of nicardipine hydrochloride for the treatment of various cerebrovascular disorders. Clin Rep (Jap). 1982;16:257-262.
113. Hiramine T. Clinical effects of nicardipine hydrochloride (Perdipine) on cerebrovascular disorders. Med Consult New Remed (Jap). 1983;20:97-102.
114. Kuriyama Y, Sawada T, Niimi T, Naritomi H, Kinugawa H, Fukushima M, Kaneko T. Effects of nicardipine and nifedipine on cerebral circulation in cerebrovascular disorders. J Cereb Blood Flow Met. 1983;3 (Suppl. 1):560-561.
115. Iijima K. Effects of perdipine on post-apoplectic disorders and cerebral arteriosclerosis. Clin Rep (Jap). 1983;17:153-162.
116. Ikeda T. Clinical trial of YC-93 (Nicardipine HCl) in patients with cerebral vascular disorders and cerebral blood flow disturbances. Clin Rep (Jap). 1983;17:263-277.
117. Iwabuchi S. Effects and safety of nicardipine hydrochloride in patients with higher cerebral dysfunction. Med Consult New Remed (Jap). 1987;24:169.
118. De Cabo JP. Estudio clìnico de un derivado piridìnico nitrofenilado, la nicardipina, como agente vasodilatator cerebral. Rev Esp Geriatr Gerontol. 1984;19:311-315.
119. Vintrò Molins C, Viaplana Màs JM. Ensayo clìnico a doble ciego parallelo de nicardipina frente a placebo en pacientes con insuficiencia vascular cerebral crònica. Med Clin (Barc). 1985;84:308-311.
120. Gonzàles-Elipe J, Romero J, Lozano R. Nicardipine in the treatment of the cerebral ischemic attack sequelae: Double-blind study versus placebo. New York: International Symposium on Calcium Antagonists; 1987.
121. Spanish Group of Nicardipine Study in Vascular Dementia. An experimental, randomized, double-blind, placebo-controlled clinical trial to investigate the effect of nicardipine on cognitive function in patients with vascular dementia. Rev Neurol. 1999;15;28:835-845.
122. Gonzalez-Gonzalez JA, Lozano RA. Study of the tolerability and effectiveness of nicardipine retard in cognitive deterioration of vascular origin. Rev Neurol. 2000;30:719-728.
123. De Fabritiis A, Pili C, Scondotto G, Borgatti E. Modificazioni delle resistenze vascolari cerebrali valutate mediante tecnica del doppler carotideo: effetti della nicardipina verso cinnarizina. Giorn It Angiol. 1985;5:41-59.
124. Puccinelli F, Pieraccini F, Tomei GP, Gargiulo L. L' ipertensione arteriosa nella fase riabilitativa dell' ictus cerebrale. Clin Ter. 1989;130:29-35.
125. Scarzella L, Bergamasco B. La nicardipina nella terapia dell' ipertensione arteriosa dell' anziano affetto da sindrome psico-organica. Clin Ter. 1989;130:171-178.
126. Weir B. Calcium antagonist, cerebral ischemia and vasospasm. Can J Neurol Sci. 1984;11:239-246.
127. Lopez-Arrieta JM, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev. 2002:CD000147.
128. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in vascular dementia. Expert Opin Pharmacother.. 2004;5:1399-1410.
129. Pantoni L, del Ser T, Soglian AG, Amigoni S, Spadari G, Binelli D, Inzitari D. Efficacy and safety of nimodipine in subcortical vascular dementia: A randomized placebo-controlled trial. Stroke. 2005;36:619-624.
130. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1053.
131. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
132. Birkenhäger WH, Staessen JA. Progress in cardiovascular diseases: Cognitive function in essential hypertension. Prog Cardiovasc Dis. 2006;49:1-10.
133. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhäger WH, Babarskiene MR, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T, Lilov E, Moisseyev V, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Fagard R. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352:1347-1351.
134. Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, Humala N, Seror I, Bartholomew S, Rosendorff C, Pasinetti GM. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest. 2007;117:3393-3402.